Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT03975062

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03975062
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03975062. Randomized; single masking; primary purpose prevention. Start 2017-12-28 (actual); primary completion 2020-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)
Acronym
RE-SOUND
Intervention (Drug)
dabigatran etexilate
Lead sponsor
Ural State Medical University (class: other)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct03975062
Content hash
f6bb3aaded7a2f92d687dafd4077cf4dcc5ce0c828d3e558de3d4df33f01cc6b